Targeted drug trial offers new hope for tough pancreatic cancers
NCT ID NCT07283705
Summary
This study is testing whether a new drug called BMS-986504 can help control pancreatic cancer when given alongside standard chemotherapy and, for some patients, surgery. It is for people whose cancer has a specific genetic change called an MTAP deletion. The main goals are to see if the combination is safe and if it can help slow the cancer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE 2 STUDY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.